Galapagos (GLPG) to Release Quarterly Earnings on Wednesday

Galapagos (NASDAQ:GLPG) will be posting its quarterly earnings results after the market closes on Wednesday, October 30th. Analysts expect Galapagos to post earnings of ($0.06) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Galapagos Stock Performance

GLPG opened at $30.24 on Wednesday. The business has a fifty day simple moving average of $28.66 and a 200 day simple moving average of $27.83. Galapagos has a 1 year low of $24.16 and a 1 year high of $42.46.

Wall Street Analysts Forecast Growth

GLPG has been the subject of a number of recent research reports. Leerink Partnrs raised shares of Galapagos to a “hold” rating in a research report on Monday, September 9th. Leerink Partners assumed coverage on shares of Galapagos in a report on Monday, September 9th. They issued a “market perform” rating and a $24.00 price objective for the company. Finally, Raymond James cut shares of Galapagos from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, Galapagos presently has a consensus rating of “Hold” and an average price target of $31.00.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.